Wockhardt Management
Management criteria checks 4/4
Wockhardt's CEO is Murtaza Khorakiwala, appointed in Apr 2009, has a tenure of 15.75 years. total yearly compensation is ₹21.20M, comprised of 95.3% salary and 4.7% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth ₹408.20M. The average tenure of the management team and the board of directors is 15.8 years and 7.7 years respectively.
Key information
Murtaza Khorakiwala
Chief executive officer
₹21.2m
Total compensation
| CEO salary percentage | 95.3% |
| CEO tenure | 15.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 15.8yrs |
| Board average tenure | 7.7yrs |
Recent management updates
Recent updates
What Wockhardt Limited's (NSE:WOCKPHARMA) 31% Share Price Gain Is Not Telling You
Dec 17
Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up
Nov 02What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You
Aug 20Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jul 27Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Jun 30Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation
Jun 22Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%
Feb 21There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump
Dec 19There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues
Oct 14Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Jun 23Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Feb 18Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jan 04Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being
Jul 26Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
May 18Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Jan 26
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?
Dec 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -₹3b |
| Jun 30 2024 | n/a | n/a | -₹3b |
| Mar 31 2024 | ₹21m | ₹20m | -₹5b |
| Dec 31 2023 | n/a | n/a | -₹5b |
| Sep 30 2023 | n/a | n/a | -₹5b |
| Jun 30 2023 | n/a | n/a | -₹6b |
| Mar 31 2023 | ₹24m | ₹23m | -₹6b |
| Dec 31 2022 | n/a | n/a | -₹6b |
| Sep 30 2022 | n/a | n/a | -₹5b |
| Jun 30 2022 | n/a | n/a | -₹3b |
| Mar 31 2022 | ₹24m | ₹17m | -₹2b |
| Dec 31 2021 | n/a | n/a | -₹787m |
| Sep 30 2021 | n/a | n/a | -₹567m |
| Jun 30 2021 | n/a | n/a | -₹867m |
| Mar 31 2021 | ₹24m | ₹24m | -₹3b |
| Dec 31 2020 | n/a | n/a | -₹2b |
| Sep 30 2020 | n/a | n/a | -₹3b |
| Jun 30 2020 | n/a | n/a | -₹3b |
| Mar 31 2020 | ₹24m | ₹24m | -₹2b |
| Dec 31 2019 | n/a | n/a | -₹1b |
| Sep 30 2019 | n/a | n/a | -₹2b |
| Jun 30 2019 | n/a | n/a | -₹2b |
| Mar 31 2019 | ₹24m | ₹24m | -₹3b |
| Dec 31 2018 | n/a | n/a | -₹3b |
| Sep 30 2018 | n/a | n/a | -₹3b |
| Jun 30 2018 | n/a | n/a | -₹3b |
| Mar 31 2018 | ₹24m | ₹19m | -₹6b |
Compensation vs Market: Murtaza's total compensation ($USD246.47K) is below average for companies of similar size in the Indian market ($USD577.74K).
Compensation vs Earnings: Murtaza's compensation has been consistent with company performance over the past year.
CEO
Murtaza Khorakiwala (51 yo)
15.8yrs
Tenure
₹21,200,000
Compensation
Dr. Murtaza Habil Khorakiwala serves as the Managing Director of Wockhardt Ltd. since April 2009 and has been its Executive Director since March 31, 2009. Dr. Khorakiwala serves as a Director of Khorakiwal...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 20.9yrs | ₹36.50m | 0.37% ₹ 829.1m | |
| MD & Executive Director | 15.8yrs | ₹21.20m | 0.18% ₹ 408.2m | |
| Executive Director | 15.8yrs | ₹21.20m | 0.17% ₹ 389.8m | |
| Chief Financial Officer | 2.6yrs | no data | 0.0080% ₹ 18.0m | |
| Chief Scientific Officer of New Drug Discovery | no data | ₹1.71m | 0.036% ₹ 80.9m | |
| Senior Vice President of Legal | no data | no data | 0.0077% ₹ 17.5m | |
| Chief Human Resource Officer | no data | no data | no data | |
| Senior Vice President of Business Development | no data | ₹1.61m | no data | |
| Head of Global Regulatory Affairs | 11yrs | no data | no data | |
| President of Supply Chain | no data | no data | no data | |
| Managing Director of Wockhardt UK | no data | no data | no data | |
| President of Manufacturing | no data | no data | no data |
15.8yrs
Average Tenure
57yo
Average Age
Experienced Management: WOCKPHARMA's management team is seasoned and experienced (15.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 20.9yrs | ₹36.50m | 0.37% ₹ 829.1m | |
| MD & Executive Director | 15.8yrs | ₹21.20m | 0.18% ₹ 408.2m | |
| Executive Director | 15.8yrs | ₹21.20m | 0.17% ₹ 389.8m | |
| Non-Executive Independent Director | 4.4yrs | ₹1.10m | no data | |
| Non-Executive & Independent Director | 8.2yrs | ₹1.70m | no data | |
| Non-Executive Non- Independent Director | 7.3yrs | ₹300.00k | no data | |
| Non Executive Independent Director | less than a year | no data | 0.00012% ₹ 270.6k | |
| Independent Director | 1.5yrs | ₹1.00m | 0.000060% ₹ 135.3k |
7.7yrs
Average Tenure
66.5yo
Average Age
Experienced Board: WOCKPHARMA's board of directors are considered experienced (7.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 04:34 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wockhardt Limited is covered by 19 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Sarabjit Nangra | Angel Broking Private Limited |